Login
$NMRA
$0.40 +$0.03 (7.63%) After hours

$NMRA SEC Filings

Filed On Filing
16 Nov 2026 10-Q
16 Nov 2026 8-K: Results of Operations and Financial Condition

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

30 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

21 Aug 2026 Form 4: Aurora Daljit Singh, See Remarks

Received 134,452 shares by exercise or conversion ($96.8K) · Sold 134,452 shares ($204K) · Granted 200,000 Stock Option (Right to Buy) · 2 more

21 Aug 2026 Form 4: Berns Paul L, Director

Granted 500,000 Stock Option (Right to Buy)

21 Aug 2026 Form 4: Duncan Jason, See Remarks

Granted 375,000 Stock Option (Right to Buy)

21 Aug 2026 Form 4: Milligan Michael Lee, See Remarks

Granted 175,000 Stock Option (Right to Buy)

21 Aug 2026 Form 4: Pinto Joshua, Director

Granted 500,000 Stock Option (Right to Buy)

21 Aug 2026 144
20 Aug 2026 144
19 Aug 2026 Form 4: Aurora Daljit Singh, See Remarks

Received 112,686 shares by exercise or conversion ($81.1K) · Sold 146,706 shares ($220K) · Received 69,149 shares by exercise or conversion ($49.8K) · 3 more

19 Aug 2026 144
18 Aug 2026 144
17 Aug 2026 144
14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026

27 Jul 2026 8-K: Other Events

Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026

15 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

29 May 2026 Form 4: Burow Kristina, Director

Granted 80,000 Stock Option (Right to Buy)

29 May 2026 Form 4: Fust Matthew K, Director

Granted 80,000 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support